Other options to discuss with your provider Beyond semaglutide and tirzepatide, the GLP-1 landscape is expanding
D., Ayuketah, A., Brychta, R., Cai, H., Cassimatis, T., Chen, K
This finding underscores the conformational plasticity of GPCRs and the limitations of in silico approaches for identifying novel allosteric sites on class B receptors
Your body is running thousands of these signals every day
The simple answer is that all medicines have risks, but some are riskier than others
Every state has its own requirements for establishing a valid prescriber-patient relationship via telehealth, and oversight is tightening (New Yorks May 2025 telehealth controlled-substance rules signal the direction)